Neurological biomarkers help in early diagnosis and better management of neurological diseases like Alzheimer's disease, Parkinson's disease and various types of brain cancer. Biomarkers play an important role in developing personalized treatment strategies. The growing focus on precision medicine is driving the demand for neurological biomarkers to develop targeted therapies. Biomarkers help identify individuals who are more likely to benefit from specific drugs and therapies. This is accelerating the adoption of personalized treatment approaches.

The global Neurological Biomarkers Market is estimated to be valued at US$ 11813.64 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increased adoption of personalized medicine is one of the key trends in the neurological biomarkers market. Biomarkers help develop personalized treatment regimens by identifying individuals who are more likely to benefit or experience side-effects from certain therapies. This enables the development of targeted drugs specific to genetic subtypes of neurological conditions. For instance, cerebrospinal fluid (CSF) biomarkers like tau and amyloid beta have emerged as potential biomarkers for early diagnosis and personalized treatment of Alzheimer's disease. Biomarkers help optimize treatment selection and facilitate stratified clinical trials. This is driving the demand for neurological biomarkers from pharmaceutical companies for precision medicine applications.

Segment Analysis

The global Neurological Biomarkers market is dominated by protein biomarkers sub segment. Protein biomarkers are diagnostic and prognostic indicators of various neurological disorders including Alzheimer's disease, Parkinson's disease, traumatic brain injuries, and stroke. They play a crucial role in drug development and clinical trials by aiding early diagnosis and helping monitor disease progression and treatment response. Increased focus on development of cost-effective and non-invasive protein biomarkers is expected to drive the sub segment growth over the forecast period.

Key Takeaways

The Global Neurological Biomarkers Market Share is expected to witness high growth over the forecast period of 2023 to 2030. The market is driven by rising prevalence of neurological disorders, growing geriatric population, and increasing R&D investments in biomarkers. The global Neurological Biomarkers Market is estimated to be valued at US$ 11813.64 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.

Regional analysis: North America is currently the dominant region for the Neurological Biomarkers market owing to rising cases of Alzheimer's, Parkinson's diseases and favorable regulatory scenario for biomarker development. However, Asia Pacific region is expected to grow at the fastest rate over the forecast period supported by rapidly developing healthcare infrastructure, increasing healthcare expenditure and growing focus of key players in the region.

Key players: Key players operating in the Neurological Biomarkers market are Knauf Gips KG, LafargeHolcim, National Gypsum Company, Saint-Gobain Group, Yoshino Gypsum Co., Ltd., ACG Materials, Anhydritec, BNZ Materials Inc., American Gypsum, Gyptec Iberica. These players are focusing on new product launches, collaborations and geographic expansions to gain market share.

For more insights, Read- https://www.insightprobing.com/neurological-biomarkers-market-size-and-share-2/